UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?

Annals of oncology, 2019-11, Vol.30, p.ix81

Gong, H.

2019

Link zum Volltext

Verfügbarkeit prüfen

Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma

Annals of oncology, 2020-04, Vol.31 (4), p.517-524

2020

Link zum Volltext

Verfügbarkeit prüfen

376P - Multidisciplinary treatments increase overall survival in patients with newly diagnosed stage IV breast cancer: An analysis of 2010–2014 SEER data

Annals of oncology, 2019-10, Vol.30, p.v137-v137

2019

Link zum Volltext

Verfügbarkeit prüfen

Multidisciplinary treatments increase overall survival in patients with newly diagnosed stage IV breast cancer: An analysis of 2010–2014 SEER data

Annals of oncology, 2019-10, Vol.30, p.v137

2019

Link zum Volltext

Verfügbarkeit prüfen

934P Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma

Annals of oncology, 2023-10, Vol.34, p.S588-S588

2023

Link zum Volltext

Verfügbarkeit prüfen

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Annals of oncology, 2023-11, Vol.34, p.S1684-S1685

2023

Link zum Volltext

Verfügbarkeit prüfen

43P Assessment of biomarker kinetics for ADG106 (anti-CD137 agonist) as monotherapy or combined with toripalimab

Annals of oncology, 2021-12, Vol.32, p.S1389-S1390

2021

Link zum Volltext

Verfügbarkeit prüfen

509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

Annals of oncology, 2023-11, Vol.34, p.S1665-S1666

2023

Link zum Volltext

Verfügbarkeit prüfen

LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

Annals of oncology, 2023-10, Vol.34, p.S1305-S1306

2023

Link zum Volltext

Verfügbarkeit prüfen

741P Phase I results demonstrate highly differentiated safety and PK profile of ADG126, a masked anti-CTLA-4 SAFEbody in patients with advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S882-S883

2022

Link zum Volltext

Verfügbarkeit prüfen

518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Annals of oncology, 2023-11, Vol.34, p.S1671-S1672

2023

Link zum Volltext

Verfügbarkeit prüfen

1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Annals of oncology, 2023-10, Vol.34, p.S755-S756

2023

Link zum Volltext

Verfügbarkeit prüfen

137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors

Annals of oncology, 2021-12, Vol.32, p.S1436-S1437

2021

Link zum Volltext

Verfügbarkeit prüfen

1010P Real-world dosing of regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Interim analysis (IA) of the observational REFINE study

Annals of oncology, 2020-09, Vol.31, p.S699-S700

2020

Link zum Volltext

Verfügbarkeit prüfen

376PMultidisciplinary treatments increase overall survival in patients with newly diagnosed stage IV breast cancer: An analysis of 2010–2014 SEER data

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial

Annals of oncology, 2023-02, Vol.34 (2), p.163-172

2023

Link zum Volltext

Verfügbarkeit prüfen

Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis

Annals of oncology, 2009-08, Vol.20 (8), p.1337-1343

2009

Link zum Volltext

Verfügbarkeit prüfen

200P Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score

Annals of oncology, 2023-11, Vol.34, p.S1552

2023

Link zum Volltext

Verfügbarkeit prüfen

104P The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy

Annals of oncology, 2023-11, Vol.34, p.S1511

2023

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment

Annals of oncology, 2022-01, Vol.33 (1), p.109-111

2022

Link zum Volltext

Verfügbarkeit prüfen

475P Diffusion kurtosis imaging signature in predicting the chemotherapeutic response of colorectal liver metastases: The result of the FDZL-MRinCLM study

Annals of oncology, 2020-09, Vol.31, p.S443-S443

2020

Link zum Volltext

Verfügbarkeit prüfen

135P c-Ros oncogene 1 receptor tyrosine kinase (ROS1) partners identified by next-generation sequencing in Chinese patients with solid tumours

Annals of oncology, 2020-09, Vol.31, p.S293-S294

2020

Link zum Volltext

Verfügbarkeit prüfen

Tumor-infiltrating lymphocytes and pathologic complete response among the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP): Single center experience

Annals of oncology, 2018-11, Vol.29, p.ix10-ix10

2018

Link zum Volltext

Verfügbarkeit prüfen

A nomogram for predicting the malignant diagnosis of BI-RADS US category 4A lesions in women with dense breast tissue

Annals of oncology, 2019-05, Vol.30, p.iii42-iii42

2019

Link zum Volltext

Verfügbarkeit prüfen

1156P - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma

Annals of oncology, 2019-10, Vol.30, p.v468-v468

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 86

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieChinese Physics Letters

PublikationsformBuchkapitel

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(86)

Sprache

Englisch
(86)

Erscheinungsjahr

n.n

Kollektion

Free E-Journal (出版社公開部分のみ）
(86)
Ovid SocietyJournals and Single Titles
(86)
Ingenta
(13)
MEDLINE
(5)

Menü

Weitere Dienste

Einstellungen

Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?

Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma

376P - Multidisciplinary treatments increase overall survival in patients with newly diagnosed stage IV breast cancer: An analysis of 2010–2014 SEER data

Multidisciplinary treatments increase overall survival in patients with newly diagnosed stage IV breast cancer: An analysis of 2010–2014 SEER data

934P Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

43P Assessment of biomarker kinetics for ADG106 (anti-CD137 agonist) as monotherapy or combined with toripalimab

509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

741P Phase I results demonstrate highly differentiated safety and PK profile of ADG126, a masked anti-CTLA-4 SAFEbody in patients with advanced solid tumors

518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors

1010P Real-world dosing of regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Interim analysis (IA) of the observational REFINE study

376PMultidisciplinary treatments increase overall survival in patients with newly diagnosed stage IV breast cancer: An analysis of 2010–2014 SEER data

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial

Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis

200P Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score

104P The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy

SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment

475P Diffusion kurtosis imaging signature in predicting the chemotherapeutic response of colorectal liver metastases: The result of the FDZL-MRinCLM study

135P c-Ros oncogene 1 receptor tyrosine kinase (ROS1) partners identified by next-generation sequencing in Chinese patients with solid tumours

Tumor-infiltrating lymphocytes and pathologic complete response among the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP): Single center experience

A nomogram for predicting the malignant diagnosis of BI-RADS US category 4A lesions in women with dense breast tissue

1156P - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma

Aktive Filter

Suchergebnisse filtern